Pipeline

OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. OWP has a vision to become the leading neuroscience company for the treatment of pediatric and adolescent patients, focused on supporting physicians, nurse practitioners, and physician assistants in psychiatry and neurology who manage their care.

Since 2019 , the company has announced progress towards the development of its first five liquid formulations, including lamotrigine, topiramate, quetiapine fumarate, duloxetine hydrochloride, and atomoxetine hydrochloride. Offering an important delivery alternative for drugs often used for epilepsy, bipolar disorder, migraine, schizophrenia, and ADHD, the first five represent several oral liquid medications in neuroscience that the company hopes to commercialize over the next several years via 505(b)(2) applications, in keeping with its pipeline of reformulated, approved therapeutics with no currently available liquid formulation.